Influence of selenium-enriched yeast supplementation on biomarkers of oxidative damage and hormone status in healthy adult males: A clinical pilot study

Cancer Epidemiology Biomarkers and Prevention

Volumn 11, Issue 11, 2002, Pages 1459-1465

  El Bayoumy, Karam ^a   Richie Jr , John P ^a   Boyiri, Telih ^a   Komninou, Despina ^a   Prokopczyk, Bogdan ^a   Trushin, Neil ^a   Kleinman, Wayne ^a   Cox, Julie ^a   Pittman, Brian ^a   Colosimo, Steven ^a  

^a AMERICAN HEALTH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; BIOLOGICAL MARKER; GLUTATHIONE; PROSTATE SPECIFIC ANTIGEN; SELENIUM; TESTOSTERONE;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; HORMONE METABOLISM; HUMAN; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; URINALYSIS; YEAST;

ADULT; BIOLOGICAL MARKERS; CREATININE; DEOXYGUANOSINE; DIETARY SUPPLEMENTS; DIHYDROTESTOSTERONE; DOUBLE-BLIND METHOD; FACTOR IX; GLUTATHIONE; HUMANS; MALE; PATIENT COMPLIANCE; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; REFERENCE VALUES; SELENIUM; TIME FACTORS; TREATMENT OUTCOME; YEAST, DRIED;

EID: 0036845683     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Willett, W. C., Polk, B. F., Morris, J. S., Stampfer, M. J., Pressel, S., Rosner,. B., Taylor, J. O., Schneider, K., and Hames, C. G. Prediagnostic serum selenium and risk of cancer. Lancet, 2: 130-134, 1983.
2. Clark, L. C., and Alberts, D. S. Selenium and cancer: Risk or protection? J. Natl. Cancer Inst. (Bethesda), 87: 473-475, 1995.
3. van den Brandt, P. A., Goldbohm, R. A., van't Veer, P., Bode, P., Dorant, E., Hermus, R. J., and Sturmans, F. A prospective cohort study on selenium status and the risk of lung cancer. Cancer Res., 53: 4860-4865, 1993.
4. Kabuto, M., Imai, H., Yonezawa, C., Neriishi. K., Akiba, S., Kato, H., Suzuki, T., Land, C. E., and Blot, W. J. Prediagnostic serum selenium and zinc levels and subsequent risk of lung and stomach cancer in Japan. Cancer Epidemiol. Biomark. Prev., 3: 465-469, 1994.
5. El-Bayoumy, K. The role of selenium in cancer prevention. In: V. T. DeVita. S. Hellman, and S. A. Rosenberg (eds.), Cancer Prevention, pp. 1-15. Philadelphia: J. B. Lippincott Co., 1991.
6. Webber, M. M., Perez-Ripoll, E. A., and James, G. T. Inhibitory effects of selenium on the growth of DU-145 human prostate carcinoma cells in vitro. Biochem. Biophys. Res. Commun., 130: 603-609, 1985.
7. Blot, W. J., Li, J. Y., Taylor, P. R., Guo, W., Dawsey, S., Wang, G. Q., Yang, C. S., Zheng, S. F., Gail, M., Li, G. Y., Yu, V., Liu, J., Tangrea, J., Sun, Y., Liu, F., Jr., Fraumeni, J. F., Zhang, Y. H., and Li, B. Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J. Natl. Cancer Inst. (Bethesda), 85: 1483-1492, 1993.
8. Brooks, J. D., Metter, E. J., Chan, D. W., Sokoll, L. J., Landis, P., Nelson. W. G., Muller, D., Andres, R., and Carter, H. B. Plasma selenium level before diagnosis and the risk of prostate cancer development. J. Urol., 166: 2034-2038, 2001.
9. El-Bayoumy, K. The protective role of selenium on genetic damage and on cancer. Mutat. Res., 475: 123-139, 2001.
10. Greenwald, P., and Lieberman, R. Chemoprevention trials for prostate cancer. In: L. W. K. Chung, W. B. Isaacs, and J. W. Simons (eds.), Prostate Cancer: Biology, Genetics, and the New Therapeutics, pp. 499-518. Totowa, NJ: Humana Press Inc., 2000.
11. Brooks, J. D., and Nelson, W. G. Chemoprevention of prostate cancer. In: L. W. K. Chung, W. B. Isaacs, and J. W. Simons (eds.). Prostate Cancer: Biology, Genetics, and the New Therapeutics, pp. 365-375. Totowa; NJ: Human Press Inc., 2000.
12. Platz, E. A., and Helzlsouer, K. J. Selenium, zinc, and prostate cancer. Epidemiol. Rev., 23: 93-101, 2001.
13. Clark, L. C., Dalkin, B., Krongrad, A., Combs, G. F., Jr., Tumbull, B. W., Slate, E. H., Witherington, R., Herlong, J. H., Janosko, E., Carpenter, D., Borosso, C., Falk, S., and Rounder, J. Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial. Br. J. Urol., 81: 730-734, 1998.
14. Clark, L. C., Combs, G. F., Jr., Turnbull, B. W., Slate, E. H., Chalker, D. K., Chow, J., Davis, L. S., Glover, R. A., Graham, G. F., Gross, E. G., Krongrad, A., Lesher, J. L., Jr., Park, H. K., Sanders, B. B., Jr., Smith, C. L., and Taylor, J. R. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. J. Am. Med. Assoc., 276: 1957-1963, 1996.
15. Duffield-Lillico, A. J., Reid, M. E., Turnbull, B. W., Combs, G. F., Jr., Slate, E. H., Fischbach, L. A., Marshall, J. R., and Clark, L. C. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: A summary report of the Nutritional Prevention Cancer Trial. Cancer Epidemiol. Biomark. Prev., 11: 630-639, 2002.
16. Rayman, M. P. The importance of selenium to human health. Lancet, 356: 233-241, 2000.
17. Klein, E. A., Thompson, I. M., Lippman, S. M., Goodman, P. J., Albanes, D., Taylor, P. R., and Coltman, C. SELECT: The Selenium and Vitamin E Cancer Prevention Trial: Rationale and design. Prostate Cancer Prostatic Dis., 3: 145-151, 2000.
18. Hoque, A., Albanes, D., Lippman, S. M., Spitz. M. R., Taylor, P. R., Klein, E. A., Thompson, M., Goodman, P., Stanford, J. L., Crowley, J. J., Coltman, C. A., and Santella, R. M. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control, 12: 627-633, 2001.
19. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer statistics, 2002. CA Cancer J. Clin., 52: 23-47, 2002.
20. Garnick, M. B. Prostate cancer screening, diagnosis, and management. Ann. Int. Med., 118: 804-818, 1993.
21. Kolonel, L. N., Hinds, M. W., and Hankin, J. H. Cancer patterns among migrant and native-born Japanese in Hawaii in relation to smoking, drinking and dietary habits. In: H. V. Gelboin, B. MacMahon. T. Matsushima, T. Sugimura, S. Takayama, and H. Takebe (eds.), Genetics and Environmental Factors in Experimental and Human Cancer, pp. 327-340. Tokyo: Japan Scientific Society Press, 1980.
22. Breslow, N., Chan, C. W., Dhom, G., Drury, R. A. B., Franks, L. M., Gellei, B., Lee, Y. S., Lundberg S., Spanke, B., Sternby, N. H., and Tulinium. H. Latent carcinoma of the prostate at autopsy in seven areas. Int. J. Cancer, 20: 680-688, 1977.
23. Yantani, R., Kusano, I., Shiraishi, T., Hyashi, T., and Stemmermann, G. N. Latent prostatic carcinoma: Pathological and epidemiological aspects. Jpn. J. Clin. Oncol., 19: 319-326, 1989.
24. Wynder, E. L., and Fair, W. R. Prostate cancer: Nutrition adjunct therapy, J. Urol., 156: 1364-1365, 1996.
25. Greenwald, P. Principles of cancer prevention: Diet and nutrition. In: V. T. DeVita. Jr., S. Hellman. and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 167-180. Philadelphia: J. B. Lippincott, 1989.
26. Rohan, T. E., Howe, G. R., Burch, J. D., and Jain, M. Dietary factors and risk of prostate cancer: A case control study in Ontario, Canada. Cancer Causes Control, 6: 145-154, 1995.
27. Anderson, S. O., Wolk, A., Bergstrom, R., Giovannucci, E., Lindgren, C., Baron, J., and Adami, H. O. Energy, nutrient intake and prostate cancer risk: A population based case-control study in Sweden. Int. J. Cancer, 68: 716-722, 1996.
28. Mettlin, C., Selenskas, S., Natarajan, N., and Huben, R. β-Carotene and animal fats and their relationship to prostate cancer risk. A case-control study. Cancer (Phila.), 64: 85-94, 1989.
29. Block, G., Patterson, B., and Subar, A., Fruit, vegetables and cancer prevention: A review of the epidemiological evidence. Nutr. Cancer, 18: 1-29, 1992.
30. Jacobs, D. R., Jr., Marquart, L., Slavin, J., and Kushi, L. H. Whole-grain intake and cancer: An expanded review and meta-analysis. Nutr. Cancer, 30: 85-96, 1998.
31. Hebert, J. R., Hurley, T. G., Olendzki, B. C., Teas, J., Ma, Y., and Hampl, J. S. Nutritional and socioeconomic factors in relation to prostate cancer mortality: A cross-national study. J. Natl. Cancer Inst. (Bethesda), 90: 1637-1647, 1998.
32. Steinberg, G. D., Carter, B. S., Beaty, T. H., Childs, B., and Walsh, P. C. Family history and the risk of prostate cancer. Prostate, 17: 337-347, 1990.
33. Woolf, C. M. An investigation of the familial aspects of carcinoma of the prostate. Cancer (Phila.), 3: 739-744, 1960.
34. Cannon, L., Bishop, D. T., Skolnick, M., Hunt, S., Lyon, J. L., and Smart, C. R. Genetic epidemiology of prostate cancer in the Utah Mormon genealogy. Cancer Surv., 1: 47-69, 1982.
35. Whittemore, A. S., Wu, A. H., Kolonel, L. N., John, E. M., Gallagher, R. P., Howe, G. R., West, D. W., Teh, C. Z., and Stamey, T. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am. J. Epidemiol., 141: 732-740, 1995.
36. Coetzee, G. A., and Ross, R. K. Re: Prostate cancer and the androgen receptor. J. Natl. Cancer Inst. (Bethesda), 86: 872-873, 1994.
37. Imperato-McGinley, J., Guerrero, L., Gautier, T., and Peterson, R. E. Steroid 5α-reductase deficiency in man: An inherited form of male pseudohermaphroditism. Science (Wash. DC), 186: 1212-1215, 1974.
38. Walsh, P. C., Madden, J. D., Marrod, M. J., Goldstein, J. L., MacDonald, P. C., and Wilson, J. P. Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N. Engl. J. Med., 291: 944-949, 1974.
39. Bruun, E., Frandsen, H., Nielsen, K., Rasmussen, L. D., Vinnergaard, T., and Frimodt-Moller, C. Dihydrotestosterone measured in core biopsies from prostatic tissues. Am. J. Clin. Oncol., 11 (Suppl. 2): S27-S29, 1988.
40. Habib, F. K., Bissas, A., Neill, W. A., Busuttil, A., and Chisholm, G. D. Flow cytometric analysis of cellular DNA in human prostate cancer: Relationship to 5α-reductase activity of the tissue. Urol. Res., 17: 239-243, 1989.
41. Ross, R., Bernstein, L., Judd, H., Hanisch, R., Pike, M., and Henderson, B. Serum testosterone levels in healthy young black and white men. J. Natl. Cancer Inst. (Bethesda), 76: 45-48, 1986.
42. Prehn, R. T. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res., 59: 4161-4164, 1999.
43. Brawley, O. W., Ford, L. G., Thompson, I., Perlman, J. A., and Kramer, B. S. 5-α-Reductase inhibition and prostate cancer prevention. Cancer Epidemiol. Biomark. Prev., 3: 177-182, 1994.
44. Burks, D. A., and Littleton, R. H. The epidemiology of prostate cancer in black men. Henry Ford Hosp. Med. J., 40: 89-92, 1992.
45. Ross, R. K., and Henderson, B. E. Do diet and androgens alter prostate cancer risk via a common etiologic pathway? J. Natl. Cancer Inst. (Bethesda), 86: 252-254, 1994.
46. Pienta, K. J., and Esper, P. S. Risk factors for prostate cancer. Ann. Int. Med., 118: 793-803, 1993.
47. Gormley, G. J. Chemoprevention strategies for prostate cancer: The role of 5-α-reductase inhibitors. J. Cell. Biochem., 16H: 113-117, 1992.
48. Coffey, D. S., and Pienta, K. J. New concepts in studying the control of normal and cancer growth of the prostate. In: A. R. Liss (ed.), Current Concepts and Approaches to the Study of Prostate Cancer, pp. 1-73. New York: Alan R. Liss Inc., 1987.
49. Pienta, K. J., Partin, A. W., and Coffey, D. S. Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res., 49: 2525-2532, 1989.
50. Grino, P. B., Griffin, J. E., and Wilson, J. D. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology, 126: 1165-1172, 1990.
51. Cohen, S. A., and Michaud, D. P. Synthesis of a fluorescent derivatizing reagent, 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate, and its application for the analysis of hydrolysate amino acids via high performance liquid chromatography. Anal. Biochem., 211: 279-287, 1993.
52. Cohen, S, A., De Antonis, K., and Michaud, D. P. Compositional protein analysis using 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate, a novel derivatization reagent. In: R. H. Angeletti (ed.), Techniques in Protein Chemistry IV, pp. 289-298. San Diego, CA., Academic Press, 1993.
53. Richie, J. P., Jr., Skowronski, L., Abraham, P., and Leutzinger, Y. Blood glutathione concentrations in a large-scale human study. Clin. Chem., 42: 64-70, 1996.
54. Tietze, F, Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione. Anal. Biochem., 27: 502-522, 1969.
55. Owens. C. W. I., and Belcher, R. V. A colorimetric micro-method for the determination of glutathione. J. Biochem., 94: 705-711, 1965.
56. Sohn, O. S., Blackwell, L., Mathis, J., Assad, W. W., Reddy, B. S., and El-Bayoumy, K. Excretion and tissue distribution of selenium following treatment of male F344 rats with benzylselenocyanate or sodium selenite. Drug Metab. Dispos., 19: 865-870, 1991
57. Voth-Beach, L. M., and Schrader, D. E. Graphite furnace atomic absorption spectroscopy: New approaches to matrix modification. Spectroscopy, 1: 49-59, 1986.
58. Fleiss, J. L. The Design and Analysis of Clinical Experiments. Chapter 8. Repeated Measurements Studies, pp. 220-240. New York: John Wiley & Sons, 1986.
59. Richie, J. P., Jr., Abraham, P., and Leutzinger, Y. Long-term stability of blood glutathione and cysteine levels in human subjects. Clin. Chem., 42: 1100-1105, 1996.
60. Pryor, W. A. Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity, Environ. Health Perspect., 105: 875-882, 1997.
61. Hickey, K., Do, K-A., and Green, A. Smoking and prostate cancer. Epidemiol. Rev., 23: 115-125, 2001.
62. Schafer, F. Q., and Buettner, G. R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol Med., 30: 1191-1212, 2001.
63. Richie, J. P., Jr. The role of glutathione in aging and cancer. Exp. Gerontol., 27: 615-626, 1992.
64. Locigno, R., and Castronovo, V. Reduced glutathione system: Role in cancer development, prevention and treatment (review). Int. J. Oncol., 19: 221-236, 2001.
65. Ketterer, B, Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis. Mutat. Res., 202: 343-361, 1988.
66. Hall, A. G. The role of glutathione in the regulation of apoptosis. Eur. Clin. Invest., 29: 238-245, 1999.
67. Klatt, P., and Lamas, S. Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress. Eur. J. Biochem., 267: 4928-4944, 2000.
68. Cotgreave, I. A., and Gerdes, R. G. Recent trends in glutathione biochemistry: Glutathione-protein interactions: A molecular link between oxidative stress and cell proliferation? Biochem. Biophys. Res. Commun., 242: 1-9, 1998.
69. Delmas-Beauvieux, M-C., Peuchant, E., Couchouron, A., Constans, J., Sergeant, C., Simonoff, M., Pellegrin, J-L., Leng, B., Conri, C., and Clerc, M. The enzymatic antioxidant system in blood and glutathione status in human immunodeficiency virus (HIV)-infected patients: Effects of supplementation with selenium of β-carotene. Am. J. Clin. Nutr., 64: 101-107, 1996.
70. Habib, F. K., Ross, M., Tate, R., and Chisholm, G. D. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia. Clin. Endocrinol., 46: 137-144, 1997.
71. Geller, J. Effect of finasteride, a 5 α-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J. Clin. Endocrinol. Metab., 71: 1552-1555, 1990.
72. Presti, J. C., Jr., Fair, W. R., Andriole, G., Sogani, P. C., Seidmon, E. J., Ferguson, D., Ng, J., and Gormley, G. J. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J. Urol., 148: 1201-1204, 1992.
73. Abdalla, I., Ray, P., Vaida, F., and Vijayakumar, S. Racial differences in prostate-specific antigen levels and prostate-specific antigen densities in patients with prostate cancer. Am. J. Clin. Oncol., 22: 537-541, 1999.
74. Diamandis, P. Prostate-specific antigen: A cancer fighter and a valuable messenger? Clin. Chem., 46: 896-900, 2000.